Paul M Griffin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3188330/publications.pdf

Version: 2024-02-01

42 papers

3,111 citations

279487 23 h-index 276539 41 g-index

42 all docs 42 docs citations

times ranked

42

6122 citing authors

#	Article	IF	CITATIONS
1	Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine, 2020, 383, 2320-2332.	13.9	1,000
2	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance. JAMA - Journal of the American Medical Association, 2018, 320, 984.	3.8	538
3	Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry To Identify Vancomycin-Resistant Enterococci and Investigate the Epidemiology of an Outbreak. Journal of Clinical Microbiology, 2012, 50, 2918-2931.	1.8	159
4	A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs. PLoS ONE, 2011, 6, e21914.	1.1	131
5	Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infectious Diseases, The, 2017, 17, 626-635.	4.6	108
6	Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatchâ,,¢). Vaccine, 2018, 36, 3779-3788.	1.7	93
7	Experimentally Induced Blood-Stage Plasmodium vivax Infection in Healthy Volunteers. Journal of Infectious Diseases, 2013, 208, 1688-1694.	1.9	87
8	A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. Malaria Journal, 2016, 15, 469.	0.8	82
9	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	4.6	82
10	A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines and Immunotherapeutics, 2021, 17, 1248-1261.	1.4	81
11	Efficacy of OZ439 (artefenomel) against early <i>Plasmodium falciparum</i> blood-stage malaria infection in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2016, 71, 2620-2627.	1.3	64
12	Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. Lancet Infectious Diseases, The, 2020, 20, 445-454.	4.6	60
13	Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE, 2018, 13, e0198658.	1.1	59
14	Plasmodium vivax Controlled Human Malaria Infection – Progress and Prospects. Trends in Parasitology, 2017, 33, 141-150.	1.5	56
15	Piperaquine Monotherapy of Drug-Susceptible (i> Plasmodium falciparum < /i> Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia. Journal of Infectious Diseases, 2016, 214, 105-113.	1.9	55
16	A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	43
17	Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development. Antimicrobial Agents and Chemotherapy, 2016, 60, 3669-3675.	1.4	40
18	The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1113-1119.	0.6	40

#	Article	IF	CITATIONS
19	Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission. PLoS Neglected Tropical Diseases, 2016, 10, e0005139.	1.3	39
20	DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with <i>Plasmodium falciparum</i> . Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	35
21	Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects. Vaccine, 2017, 35, 6676-6684.	1.7	34
22	An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1. Human Vaccines and Immunotherapeutics, 2016, 12, 3079-3088.	1.4	27
23	Open-Label, Single-Dose, Parallel-Group Study in Healthy Volunteers To Determine the Drug-Drug Interaction Potential between KAE609 (Cipargamin) and Piperaquine. Antimicrobial Agents and Chemotherapy, 2015, 59, 3493-3500.	1.4	24
24	Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials. BMJ Open, 2019, 9, e024224.	0.8	23
25	Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. PLoS ONE, 2019, 14, e0226320.	1.1	20
26	MALDI-TOF MS meets WGS in a VRE outbreak investigation. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 495-499.	1.3	18
27	A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary Clinical Trials Communications, 2021, 23, 100830.	0.5	18
28	Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	16
29	Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite. Infection and Immunity, 2016, 84, 2689-2696.	1.0	14
30	Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial. Diabetologia, 2018, 61, 1918-1922.	2.9	14
31	Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage <i>Plasmodium vivax</i> Infection. Journal of Infectious Diseases, 2022, 225, 1062-1069.	1.9	10
32	Fasting increases serum bilirubin levels in clinically normal, healthy males but not females: a retrospective study from phase I clinical trial participants. Journal of Clinical Pathology, 2014, 67, 529-534.	1.0	8
33	First Australian case of disseminated Mycobacterium chimaera infection post-cardiothoracic surgery. Infection, Disease and Health, 2017, 22, 1-5.	0.5	8
34	Chronic urticaria following acute hepatitis A. BMJ Case Reports, 2012, 2012, bcr2012006479-bcr2012006479.	0.2	6
35	Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC Medicine, 2021, 19, 293.	2. 3	6
36	Acute vancomycin-resistant enterococcal bacteraemia outbreak analysis in haematology patients: a case-control study. Healthcare Infection, 2015, 20, 115-123.	0.6	5

#	Article	IF	CITATIONS
37	Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial. Clinical Therapeutics, 2020, 42, 1508-1518.e1.	1.1	3
38	Delusions of Disseminated Fungosis. Case Reports in Infectious Diseases, 2014, 2014, 1-3.	0.2	2
39	Rapid identification of VRE with MALDI-TOF MS. Pathology, 2013, 45, S57.	0.3	1
40	Vancomycin-Induced Linear IgA With Mucosal and Ocular Involvement. Infectious Diseases in Clinical Practice, 2014, 22, e119-e121.	0.1	1
41	Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial Journal of Clinical Oncology, 2019, 37, e14514-e14514.	0.8	1
42	Maldi in infection control (VRE). Pathology, 2014, 46, S45.	0.3	O